- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
- Interventions
- Aflibercept, foselutoclax
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 372
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- Interventions
- Bone marrow concentration device, Placebo procedure (sham)
- Device · Procedure
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
- Conditions
- Dental Anesthesia, Anesthesia, Local, Anesthesia, Reversal
- Interventions
- OraVerse, Sham injection
- Drug · Other
- Lead sponsor
- Novocol Pharmaceutical of Canada, Inc.
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- San Francisco, California • Indianapolis, Indiana • Columbus, Ohio + 4 more
- Conditions
- Psychology, Social, Inflammation, Defeat, Social, Interaction, Social
- Interventions
- Influenza vaccine, Placebo
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
- Interventions
- CTX0E03 Drug Product and delivery device, Placebo
- Combination Product · Drug
- Lead sponsor
- ReNeuron Limited
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- QR-421a, Sham-procedure (dose cohort 1&2 only)
- Drug · Other
- Lead sponsor
- ProQR Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
- Conditions
- Chronic Pancreatitis
- Interventions
- EUS-guided celiac plexus block, Sham procedure
- Procedure
- Lead sponsor
- Orlando Health, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Ischemic Stroke
- Interventions
- Active Sphenopalatine Ganglion (SPG) Stimulation, Sham Sphenopalatine Ganglion (SPG) Stimulation
- Device
- Lead sponsor
- BrainsGate
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • Winfield, Illinois • Greensboro, North Carolina + 3 more
- Conditions
- Post-traumatic Stress Disorder
- Interventions
- Stellate Ganglion Block, Sham Stellate Ganglion Block
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more
- Conditions
- Choroidal Neovascularization, Age-related Macular Degeneration
- Interventions
- hI-con1, ranibizumab, Sham injection
- Biological · Other
- Lead sponsor
- Iconic Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- QR-421a, Sham-procedure
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Choroideremia
- Interventions
- BIIB111
- Genetic
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
- Conditions
- Overactive Bladder
- Interventions
- Active TENS, Sham TENS
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
- Drug
- Lead sponsor
- Oxurion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
- Conditions
- Chondromalacia Patella, Patellofemoral Pain Syndrome
- Interventions
- Synvisc-One™, Sham Treatment
- Device · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 15 Years to 45 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Geographic Atrophy
- Interventions
- APL-2, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
- Conditions
- Cystoid Macular Edema
- Interventions
- Pegaptanib Sodium, Control
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI insert, Sham injection
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Exenatide, Sham injection
- Drug · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteoarthritis, Knee, Knee Pain
- Interventions
- Micro Fragmented Adipose Tissue, Corticosteroid injection
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Persistent Diabetic Macular Edema
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana